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Background:  High sensitivity assays detect levels of cardiac troponin (cTn) much lower than the 99th percentile of standard assays. 
However, the prognostic utility of detectable high sensitivity cTn in stable patients undergoing elective coronary angiography has not been 
described.
methods:  We examined the relationship between plasma high-sensitivity cardiac troponin T (5th gen hs-cTnT; Roche Cobas, LOQ/99th 
percentile=13pg/mL) and incident major adverse cardiac events (MACE=death, myocardial infarction, stroke) over 3-year follow-up in 2,633 
stable subjects with preserved renal function (eGFR >60 ml/min/1.73m2) undergoing elective coronary angiography without acute coronary 
syndrome (cTnI <0.3 ng/mL).
results:  Median hs-cTnT levels within the cohort was 11.5pg/mL (interquartile range 7.1-17.6pg/mL). Higher hs-cTnT provided 
independent prediction 3-year MACE risk and 5-year mortality risk, even after adjusting for traditional risk factors (Table). Addition of hs-
cTnT to traditional risk factors reclassified risk of 3-year MACE in 10.5% subjects with MACE and 1.5% subjects without MACE (IDI 10%, 
p<0.001; NRI 12.1%, p<0.001, AUC 65.8 to 68.8, p=0.004).
Conclusion:  Detectable hs-cTnT provides independent prognostic value and reclassifies risk in stable cardiac patients.
Abbreviations: *p<0.05 **p<0.01 ***p<0.001
Unadjusted HR for 3-year 
MACE risk
Adjusted HR for 3-year 
MACE risk
Unadjusted HR for 5-year 
mortality risk
Adjusted HR for 5-year 
mortality risk
Quartile 1 (<7.1pg/
mL) 1.00 1.00 1.00 1.00
Quartile 2 (7.1-
11.4pg/mL) 1.58 (1.05-2.36)* 1.45 (0.97-2.17) 1.36 (0.87-2.13) 1.19 (0.76-1.86)
Quartile 3 (11.5-
17.5pg/mL) 1.85 (1.25-2.74)** 1.57 (1.06-2.34)* 2.26 (1.50-3.40)*** 1.81 (1.19-2.74)**
Quartile 4 (≥17.6pg/
mL) 3.89 (2.72-5.56)*** 3.02 (2.1-4.34)*** 4.93 (3.39-7.18)*** 3.50 (2.36-5.18)***
